DiaMedica Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/30/2024
DiaMedica Therapeutics Stock Forecast and Price Target
If the average 2024 price target of $7.00 recently set by prominent experts for DiaMedica Therapeutics is met, there would be a potential upside of approximately 170.27% from the last closing price in April, 2024. The high estimate is $8.00, and the low is $6.00. Even if you are not interested in DMAC stock, you should still be aware of its competitors.
170.27% Upside
DiaMedica Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
DiaMedica Therapeutics's Price has grown In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $2.78 – an increase of 100.00%. For the next seven years, experts predict that DiaMedica Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$161.52 | Buy/Sell | $178.42 | 15.16% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$276.38 | Buy/Sell | $303.65 | 15.60% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.94 | Buy/Sell | $87.82 | 21.32% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$215.50 | Buy/Sell | $299.62 | 33.87% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.13 | Buy/Sell | $111.56 | 33.93% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.56 | Buy/Sell | $77.05 | 46.88% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$75.42 | Buy/Sell | $34.00 | 52.48% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$93.10 | Buy/Sell | $85.71 | 7.41% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.25 | Buy/Sell | $17.90 | 95.12% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.03 | Buy/Sell | $20.42 | 111.97% |
DiaMedica Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, DiaMedica Therapeutics's EBITDA has grown, moving from $-12.68M to $-13.98M – an increase of 10.25%. In the next year, analysts predict that EBITDA will jump to $-31.81M – up 127.54% from the current level. According to professionals, by 2030, DiaMedica Therapeutics's EBITDA will have decreased by 539.68%, falling down to $61.47M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.10 | Buy/Sell | $33.78 | 75.44% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.13 | Buy/Sell | $52.00 | 129.14% |
DiaMedica Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, DiaMedica Therapeutics's EBIT has seen an increase, rising from $-12.70M to $-14.00M. This represents a growth of 10.24%. Analysts predict that DiaMedica Therapeutics's EBIT will increase in the upcoming year, reaching $-35.00M. This would represent an increase of 150.00%. In 2030, professionals predict that DiaMedica Therapeutics's EBIT will decrease by 500.77%, reaching $56.11M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$37.00 | Buy/Sell | $63.29 | 108.11% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.67 | Buy/Sell | $42.58 | 17.85% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.46 | Buy/Sell | $9.94 | 108.98% |
DiaMedica Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
DiaMedica Therapeutics's EPS has grown In the last four years, rising from $-0.78 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-0.67 – an increase of 100.00%. For the next seven years, experts predict that DiaMedica Therapeutics's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.34 | Buy/Sell | $25.00 | 116.05% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$32.76 | Buy/Sell | $40.00 | 32.78% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.58 | Buy/Sell | $6.00 | 21.58% |
Site Navigation
.jpg)